In MCD, a newly defined subtype of ABC DLBCL, MYD88, TLR9 and BCR signaling interact in a protein complex, the so-called the MY-T-BCR supercomplex, the presence of which may influence response to Bruton Tyrosine Kinase (BTK) inhibitors [9, 10]. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.